Hercules | Jotup

Disney Destiny Will Bring Stories of Legendary Disney Heroes and Villains to Life

Retrieved on:

수요일, 3월 20, 2024

Destiny, The Lion King, Pixar, Disney Cruise Line, Disney Wish, Light, Meyer Werft, Hercules, Life, Walt Disney Animation Studios, Multimedia, Family, Heroes and Villains, Walt Disney Imagineering, Amusement park

CELEBRATION, Fla., March 20, 2024 /PRNewswire/ -- Disney Cruise Line revealed the first details about its next ship, the Disney Destiny, as it reached a new construction milestone today with a keel laying ceremony at the Meyer Werft shipyard in Papenburg, Germany. With the good luck garnered by this maritime tradition, this ship of legends and lore is beginning to take shape.

Key Points:

The design theme of the Disney Destiny, sister to the Disney Wish and Disney Treasure, will be "Heroes and Villains," drawing on the legacy of beloved Disney stories, characters and theme park attractions, to forge a cruise vacation that will empower guests to embrace their own calling aboard every unforgettable voyage.
The Disney Cruise Line and Walt Disney Imagineering teams were inspired by the dynamic duality of every great Disney story, where opposing forces of light and dark drive characters to rise to their purpose, when developing the Disney Destiny.
To embody and embolden the theme, Disney also unveiled brand-new filigree artwork for the bow of the Disney Destiny, continuing a beloved Disney Cruise Line design tradition.
"The Disney Destiny will celebrate our most legendary Disney stories and characters, bringing them to life in new and exciting ways exclusively for Disney Cruise Line guests," said Sharon Siskie, senior vice president and general manager, Disney Cruise Line.

TFI International Acquires Hercules Forwarding

Retrieved on:

월요일, 3월 11, 2024

CFO, Acquisition, HVAC, Hercules, LTL, TSX, Transport, TFI International, 3PL, Cargo

MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced the acquisition of Hercules Forwarding, Inc. (“Hercules”), a Less-Than-Truckload (LTL) carrier with an emphasis on intra-US and US-to-Canada cross-border transportation. Founded in 1985 and family-owned with US headquarters in Vernon, California and Canadian headquarters in New Westminster, BC, Hercules utilizes a 31-terminal network and operates more than 210 trucks, close to 600 trailers and approximately 75 containers, generating more than US $100 million in annual revenues. Hercules’ non-union team focuses on direct shipper customers seeking high-quality, damage-free service across diverse end markets including consumer/retail, HVAC/building products, automotive, industrial, 3PL and food/beverage. Led by its president, Marty Burnham and CFO, Melanie Burnham, Hercules will join TFI’s LTL business segment.

Key Points:

MONTREAL, March 11, 2024 (GLOBE NEWSWIRE) -- TFI International Inc. (NYSE and TSX: TFII), a North American leader in the transportation and logistics industry, today announced the acquisition of Hercules Forwarding, Inc. (“Hercules”), a Less-Than-Truckload (LTL) carrier with an emphasis on intra-US and US-to-Canada cross-border transportation.
Hercules’ non-union team focuses on direct shipper customers seeking high-quality, damage-free service across diverse end markets including consumer/retail, HVAC/building products, automotive, industrial, 3PL and food/beverage.
Led by its president, Marty Burnham and CFO, Melanie Burnham, Hercules will join TFI’s LTL business segment.
We are pleased to welcome Marty, Melanie, and the entire Hercules team to the TFI International family.”

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on:

목요일, 3월 7, 2024

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.

Key Points:

Net loss: Net loss for the fourth quarter 2023 was $79.6 million, compared to $55.0 million for fourth quarter 2022.
Fourth quarter 2023 net loss included a non-cash charge related to stock-based compensation of $24.6 million compared to $6.7 million for fourth quarter 2022.
Phathom will host a conference call and webcast to discuss its fourth quarter and full year 2023 financial results and business highlights today, March 7, 2024, at 8:30 a.m.
Phathom believes the presentation of these non-GAAP financial measures provides useful information to management and investors regarding Phathom's results of operations.

Geron Corporation Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on:

수요일, 2월 28, 2024

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.

Key Points:

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business highlights and financial results for the fourth quarter and full year 2023.
The FDA assigned a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2024 to the NDA.
In September 2023, the European Medicines Agency (EMA) validated the Marketing Authorization Application (MAA) for imetelstat in the same proposed indication as the NDA.
Geron will host a conference call at 8:00 am ET on Wednesday, February 28, 2024, to discuss business updates and fourth quarter and full year 2023 financial results.

Hercules Capital Reports Fourth Quarter and Full-Year 2023 Financial Results

Retrieved on:

목요일, 2월 15, 2024

Banking, Professional Services, Finance, Hercules, Growth, Capital, Telephone, PIN

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2023.

Key Points:

Hercules Capital, Inc. (NYSE: HTGC) (“Hercules” or the “Company”), the largest and leading specialty financing provider to innovative venture, growth and established stage companies backed by some of the leading and top-tier venture capital and select private equity firms, today announced its financial results for the fourth quarter and full-year ended December 31, 2023.
The earnings release can be accessed at Hercules’ Investor Relations website at https://investor.htgc.com/financial-information/financial-results .
Hercules has scheduled its fourth quarter and full-year 2023 financial results conference call for February 15, 2024 at 2:00 p.m. PT (5:00 p.m.
A live webcast of the fourth quarter and full-year 2023 financial results conference call will also be available on the investor relations section of the Company’s website at investor.htgc.com .

Hercules Capital Announces New Supplemental Cash Distribution of $0.32 per Share

Retrieved on:

화요일, 2월 13, 2024

Professional Services, Finance, Hercules, Internal Revenue Code, Growth, Documentation, Interest, Policy, Capital, Life insurance

This $0.08 supplemental cash distribution will be paid out of Hercules’ undistributed taxable income (taxable income in excess of distributions paid) as of December 31, 2023.

Key Points:

This $0.08 supplemental cash distribution will be paid out of Hercules’ undistributed taxable income (taxable income in excess of distributions paid) as of December 31, 2023.
The following shows the key dates of the supplemental distribution payment:
This $0.08 supplemental cash distribution is in addition to the previously announced regular quarterly cash distribution that Hercules declared for the fourth quarter of 2023 of $0.40 per share.
Hercules' Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% to 100% of the Company’s taxable quarterly income or potential annual income for a particular year.
The percentage of QII for distributions declared for the fourth quarter ended December 31, 2023 on Hercules’ common stock is 81.44%.

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

Retrieved on:

목요일, 2월 8, 2024

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.

Key Points:

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2023, and provided a business update.
We plan to submit a BLA for the treatment of patients with anti-PD1 failed melanoma in 2H 2024.
Selling, general and administrative expenses included $4.5 million in stock-based compensation expenses for the third quarter ended December 31, 2023.
Net Loss: Net loss was $51.1 million for the third quarter ended December 31, 2023, as compared to a net loss of $39.7 million for the third quarter ended December 31, 2022.

Hercules Capital Announces Date for Release of Fourth Quarter and Full-Year 2023 Financial Results and Conference Call

Retrieved on:

목요일, 1월 25, 2024

Fintech, Professional Services, Finance, Telephone, Capital, Hercules, PIN, Growth

Hercules will release its financial results after market close that same day.

Key Points:

Hercules will release its financial results after market close that same day.
Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call.
A live webcast of the fourth quarter and full-year 2023 financial results conference call will also be available on the investor relations section of the Company’s website at investor.htgc.com .
An archived webcast replay will be available on the Company's website for at least 30 days following the conference call.

Dr. William Ruto, President of Kenya appoints Professor Patrick Verkooijen as Chancellor of the University of Nairobi

Retrieved on:

금요일, 1월 12, 2024

Nairobi, Kenya, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Dr. William Ruto, President of Kenya has appointed Professor Patrick Verkooijen, CEO of the Global Center on Adaptation, as Chancellor of the University of Nairobi.

Key Points:

Nairobi, Kenya, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Dr. William Ruto, President of Kenya has appointed Professor Patrick Verkooijen, CEO of the Global Center on Adaptation, as Chancellor of the University of Nairobi.
Commenting on the announcement, the president said: “I am thrilled that Professor Verkooijen will be leading the nation’s premier educational institution.
The University of Nairobi is and will be, during my watch, the pre-eminent incubator for African talent.”
Professor Amukowa Anangwe, Chair of the University of Nairobi said: “It is great to have Professor Patrick Verkooijen as the new Chancellor of the University of Nairobi.
The university community looks forward to realizing that ambition.”
Professor Stephen Kiama, Vice-Chancellor of the University of Nairobi said: “I want to thank Professor Verkooijen for accepting to serve as the Chancellor of the University of Nairobi.

Verona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital

Retrieved on:

화요일, 1월 2, 2024

Hercules, VRNA, Health care, COPD, Chronic obstructive pulmonary disease, Pharming, Growth, Patient, Pharma, Creditor, Senior

LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).

Key Points:

LONDON and RALEIGH, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), announces it and its wholly-owned subsidiary, Verona Pharma, Inc. (the “Company”), have entered into a debt financing facility (“debt facility”) providing the Company with access to up to $400 million from funds managed by Oxford Finance LLC (“Oxford”) and Hercules Capital, Inc. (NYSE: HTGC) (“Hercules”) (collectively, the “Lenders”).
The debt facility replaces the existing facility of up to $150 million with an affiliate of Oxford.
Verona Pharma will pay only interest on the outstanding loans under the debt facility for the first 53 months with the outstanding principal of the loans under the debt facility amortized over the subsequent 7 months.
The $20 million drawn and fees and associated costs due to Oxford on the discharge of the existing debt facility will be paid to Oxford on closing of the debt facility.